Clinical Trials Browser

Adenocarcinoma of Endometrium

Malignant Neoplasms of Female Genital Organs

Breast Neoplasms, Neoplasm Metastasis

Locoregional Recurrence

Anatomic Stage III Breast Cancer AJCC v8

Breast Neoplasms

Advanced Breast Carcinoma

Ovarian Neoplasms

Breast Neoplasms

ER-Positive Breast Cancer

Breast Neoplasms

Neoplasm Metastasis

Melanoma, Neoplasm Metastasis

Breast Neoplasms

Brest Cancer

Ovarian Neoplasms, Endometrial Neoplasms

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Carcinoma, Lobular

Breast Neoplasms

Hormone Receptor Positive Breast Carcinoma

Breast Cancer Metastatic

Breast Cancer Metastatic

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms

HER2-positive Breast Cancer

Salivary Gland Neoplasms

Breast Neoplasms, Neoplastic Cells, Circulating

Ovarian Neoplasms

Breast Neoplasms

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Advanced Breast Cancer

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

Breast Neoplasms

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

ER+ Breast Cancer

Clinical Trials

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

RaPhLRR

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

GERTRUDE

EPIBREAST

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NETHER

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

ABIGAIL

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

ITHRAN

Palbociclib After CDK and Endocrine Therapy (PACE)

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

ABC-SE

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

SAFIR 03

METALLICA

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Efficacy and Safety of 500mg of Fulvestrant

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

CAMERAN

Post-CDK

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

DOLAF

ASPIRE

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

PARSIFAL

MAINTAIN

TRAK-ER